

PUBLIC DECLARATION OF INTEREST

Based on the template annexed to the French order provided under article R. 1451-1 of the Public Health Code

I, Kalager	tne	undersigned	.Mette
Acknowledge the that I have now work, technolog the French Naticollegial body (nat I am aware of my obliq or have had in the past fiv gy or products fall within s onal Cancer Institute at w or bodies), commission(s)	gation to declare all interests, whether directle years, with any business, establishment of scope of the public health and health safety hich I currently hold positions or exercise of the bound of the bound of the companies or consulting firms operated the companies or consulting firms operated.	r body whose y activities of duties, or any elong or have
the persons desc conditions provid	cribed in items I and II of Art ed in said article, wilfully neg	Code "A fine of €30,000 per occurrence shall be ticle L. 1451-1 and in Article L. 1452-3 who, acglect to establish or amend a declaration of intede false information that undermines the truth	cting under the rest in order to
I am completing	this form in my capacity as	(multiple responses possible):	
		stitute: (specify positions held)	
□ a member of National Cancer	or advisor to a board, a cor	mmission, a committee, or a working group wit	hin the French
of the consultar	ncy assignment):	French National Cancer Institute: (specify the the	
The following is professional:	my number in the RPPS (Directory of Healthcare Professionals), if I an	n a healthcare
		ion of interest [PDol] whenever these intere once per year even if there have been no ch	
participate, or for to entrust to me with my attenda advice. In the ex person at the Fi prior its starting	or such provision of experi , to ascertain whether the ince at all or part of such went of any incompatibility rench National Cancer Ins J. In the event of a conflict	of the agenda for each meeting in which I t advice as the French National Cancer Institute interests that I have declared or may arise a meeting, or my participation in such provise, it is my responsibility to advise the designatitute and, if appropriate, the chairperson of of interest, my presence may cause the dens issued to be tainted, and render them null	tute may wish re compatible sion of expert nated contact of the meeting cisions made
Date:	2025		
October 7,		, electronic information and civil liberties, you have the right to access and amend	

your personal data. You may exercise this right by sending an email to: servicejuridique@institutcancer.fr

The information collected above will be processed electronically, and your declaration (except for any statements not made public) will be published on the INCa website. INCa is responsible for processing it for the purpose of preventing conflicts of interest, by comparing any declared connections with the objectives of the proposed tasks to be performed within INCa or on its behalf.

5 years, full time or part time ___ Employment Employer's Specialty or Start date End date address and Position in the Main Employer(s) discipline, if (day (optional) (day (optional) / place of practice, organisation / month / year) month / year) applicable if different University of Oslo, Norway, Department of Medicine Health Management and Health Professor Sept 2018 Ongoing Economics, University of Oslo, P.O. Box 1089 Blindern, 0317 Oslo Medicine Clinical Effectiveness Research Group. University of Oslo and Oslo University Head 2015 Ongoing Hospital, Norway Oslo University Hospital, Division of Surgery, Inflammatory Diseases and Jan 2014 Researcher Ongoing Transplantation, P.O. Box 4950 Nydalen, 0424 Oslo, Norway Liberal profession End date Start date Specialty or discipline, if Activity Place of work (day (optional)/ (day (optional) / applicable month / year) month / year) Other (volunteer work, work during retirement, etc.) End date Start date Place of work, if applicable (day (optional) (day (optional) / Activity / month / year) month / year)

Main Occupation(s), remunerated or voluntary, exercised currently and over the past

1.

Secondary occupation(s)

2.1. Participation in a decision-making body of a public or private organisation whose work, technology or products fall within the scope of the public health and health safety activities of the French National Cancer Institute or collegial body (or bodies) to which the declaration relates

This relates, in particular, to healthcare establishments, consultancy businesses and advisory board, professional bodies (learned societies, health networks, health workers' association) and associations, including patients' associations.

I have nothing to declare in this section

Organisation (company, establishment, association)	Position in the organisation	Compensation	Amount of indemnity (specify frequency if applicable)	Start date (day (optional) / month / year)	End date (day (optional)/ month / year)
		□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			
		□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			
		□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			

2.2.	Consultant, advisor or expert activity (or activities) performed for an organisation that
	falls within the scope of the public health and health safety activities of the French
	National Cancer Institute or collegial body (or bodies) to which the declaration relates

This section includes, in particular, activities as an advisor or representative, participation in an advisory board, a working group, audits or the drafting of articles or expert reports.

I have nothing to declare in this section

Organisation (company, establishment, association)	Mission	Subject (name of study, product, technology or therapeutic indication)	Compensation	Amount of indemnity (specify frequency if applicable)	Start date (day (optional) / month / year)	End date (day (optional) / month / year)
			□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			
			□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			
			□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			

2.3. Participation in scientific work and studies for public and/or private organisations that fall within the scope of the public health and health safety activities of the French National Cancer Institute or collegial body (or bodies) to which the declaration relates

2.3.1 Involvement in clinical or preclinical trials or epidemiological studies

This section should include mention of any involvement in the execution of non-clinical and preclinical trials or studies (methodological studies, analytical tests, chemical, pharmaceutical, biological, pharmacological or toxicological testing, etc.), or clinical studies, epidemiological studies, medico-economic studies and observational studies on clinical and prescribing practices (in the latter case, indicate the subject).

Membership in monitoring and follow-up committees for clinical trials must be declared in this section.

Persons acting as principal investigators in single-centre studies or as coordinators in national or international multicentre studies are considered "principal investigators." This definition does not include investigators in multicentre studies not acting in a coordinating role - even if they may be referred to elsewhere as "principals." For the purposes hereof they shall be referred to as "investigators."

I have nothing	g to declare in th	nis section					
Currently and in t	he last 5 years:						
Sponsoring organisation (company, establishment, association)	Funding organisation(s) (if other than the sponsor, and to the best of your knowledge)	Subject (name of study, product, technology or therapeutic indication)	For clinical or preclinical trials or studies, specify:	Compensation	Amount of indemnity (specify frequency if applicable)	Start date (day (optional) / month / vear)	End date (day (optional) / month / year)
The Research Council of Norway		The Nordic- European Initiative on Colorectal Cancer (NordICC)	Type of study: Single-centre study Multicentre study Your role: Principal Investigator Principal Experimenter Investigator Non-Principal Experimenter Member of a monitoring and follow-up committee	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)		01.05.2009	31.12.2031
The Research Council of Norway		European Polyp Surveillance (EPoS)	Type of study: ☐ Single-centre study ☐ Multicentre study Your role: ☐ Principal Investigator ☐ Principal Experimenter ☐ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)		1.4.2014	31.12.2017
National programme for clinical therapy research in the specialist health service, KLINBEFORSK		Colonize: Transplantation of intestinal microbiota in primary Clostridoides difficile infections	Type of study: Single-centre study Multicentre study Your role: Principal Investigator Principal Experimenter Investigator Non-Principal Experimenter Member of a monitoring and follow-up committee	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)		2019	2024

-AMED (Japan Agency for Medical Research and Development), Olympus Inc., Cybernet System Corp	EndoBRAIN International: Artificial Intelligence Aided Digagnosis of Colorectal Polys during Colonoscopy	Type of study: ☐ Single-centre study ☐ Multicentre study Your role: ☐ Principal Investigator ☐ Principal Experimenter ☐ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)	April 2019	2020
The Norwegian Cancer Association	I-Scan: Risk of colorectal cancer in inflammatory bowel disease	Type of study: Single-centre study Multicentre study Your role: Principal Investigator Principal Experimenter Investigator Non-Principal Experimenter Member of a monitoring and follow-up committee	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)	2015	2021
National programme for clinical therapy research in the specialist health service, KLINBEFORSK	Refit 2 : Microbiota therapy as treatment in irritable bowel syndrom	Type of study: ☐ Single-centre study ☐ Multicentre study Your role: ☐ Principal Investigator ☐ Principal Experimenter ☐ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)	2021	Ongoing
The Research Council of Norway	SAR: Surveillance after Adenoma Removal	Type of study: Single-centre study Multicentre study Your role: Principal Investigator Principal Experimenter Investigator Non-Principal Experimenter Member of a monitoring and follow-up committee	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)	2014	Ongoing
The Research Council of Norway	The Rapid- Cycle Re- Implementation of TRAining Facilities in Norway (TRAiN)	Type of study: ☐ Single-centre study ☐ Multicentre study Your role: ☐ Principal Investigator ☐ Principal Experimenter ☐ Investigator ☐ Non-Principal Experimenter ☐ Member of a monitoring and follow-up committee	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)	May 2020	2022

EU Horizon Europe Framework Programme (HORIZON)	Optimising Colorectal Cancer Prevention through Personalised Treatment with Artificial Intelligence - OperA	Type of study: Single-centre study Multicentre study Your role: Principal Investigator Principal Experimenter Investigator Non-Principal Experimenter Member of a monitoring and follow-up committee	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)		Begun September 2022	August 2027
---	---	--	--	--	----------------------------	-------------

2.3.2 Other scientific work

igstyle I have nothing to declare in this section

Organisation (company, establishment, association)	Subject (name of study, product, technology or therapeutic indication)	Compensation	Amount of indemnity (specify frequency if applicable)	Start date (day (optional) / month/ year)	End date (day (optional) / month / year)
		□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			
		□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			
		□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			

2.4.	Drafting of article(s) and presentation(s) at congresses, conferences, symposia,
	various public meetings or training activities organised or financially supported by
	private companies or organisations that fall within the scope of the public health and
	health safety activities of the French National Cancer Institute or collegial body (or
	bodies) to which the declaration relates

Such drafting of article(s) and presentations must be declared when they have been compensated or have been provided coverage of expenses.

2.4.1 Drafting of article(s)
I have nothing to declare in this section

Private company or organisation (society,-association)	Subject of article	Compensation	Amount of indemnity (specify frequency if applicable)	Start date (day (optional) / month / year)	End date (day (optional) / month / year)
		☐ To the declarant ☐ To an organisation of which you are a member or employee (specify)			
		☐ To the declarant ☐ To an organisation of which you are a member or employee (specify)			
		☐ To the declarant ☐ To an organisation of which you are a member or employee (specify)			

2.4.2 Oral presentation(s)

\boxtimes ı	have not	hina to	declare i	n this	section
	nave not	ııııy w	acciai c i		30011011

Inviting private company or organisation (society, association)	Location and name of the meeting	Subject of presentation, name of concerned product	Coverage of expenses	Compensation	Amount of indemnity (specify frequency if applicable)	Start date (day (optional) / month / year)	End date (day (optional) / month / year)
			o Yes	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			
			○ Yes ○ No	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			
			○ Yes ○ No	□ None □ To the declarant □ To an organisation of which you are a member or employee (specify)			

urrently and in the last	5 years:					
Nature of the work and name of the patent, product, etc.	Organisation issuing the patent or marketing the product, etc.	Share of profits	Compensation	Amount of indemnity (specify frequency if applicable)	Start date (day (optional) / month / year)	End date (day (optional), month / year)
		o Yes	□ None			
		o No	☐ To the declarant			
			☐ To an organisation of which you are a member or employee (specify)			
		o Yes	□ None			
		o No	☐ To the declarant			
			☐ To an organisation of which you are a member or employee (specify)			
		o Yes	□ None			
		o No	☐ To the declarant			
			☐ To an organisation of which you are a member or employee (specify)			

2.5. Invention or possession of a patent or a product, process or other form of non-patented intellectual property related to the scope of the public health and health safety activities of the French National Cancer Institute or collegial body (or bodies)

to which the declaration relates

3. N	Management of activities which have received funding from a profit-making organisation
	whose business activities fall within the scope of the public health and health safety
	activities of the French National Cancer Institute or collegial body (or bodies) to which
	the declaration relates

The type of funding may be in the form of subsidies or agreements for studies or research, grants or sponsorship, payments in kind, in cash, equipment.

This relates in particular to chairpersons, treasurers and members of management boards and executive committees, including for associations and learned societies.

I have nothing to declare in this section	

Body and activity for which the funding was provided	Start date (day (optional) / month / year)	End date (day (optional) / month / year)	Profit-making organisation providing the funding and amount contributed by each for the funder(s) with optional indication of the corresponding percentage of the body's budget

4.	Financial holdings in the capital of a company whose business activities falls within
	the scope of the public health and health safety activities of the French National
	Cancer Institute or collegial body (or bodies) to which the declaration relates

In this section, declare any listed or non-listed securities, including shares, bonds or other equity instruments, owned in any relevant sector or company or any subsidiary or part-owned company thereof, to the best of your immediate and reasonable knowledge. Please state the name of the establishment, company or organisation, the type of securities held, and their amount in absolute values and in percentages of capital owned.

Mutual funds, unit trusts such as SICAV or open-end funds, for which the individual has no control of the management or composition of the fund, are excluded from the declaration.

I have nothing to declare in this section		
i nave nothing to declare in this section		

Currently:

Organisation concerned	anisation concerned Type of investment		Percentage of the organisation's capital	

pecify constituency)	(day (option month / yea		ay (optio onth / ye	
Head of Research Board, Norwegian Medical Association Elected position			present	
arant.			nnity paid	i
Comment	s	(day (op	tional)/	End date (day (optiona month / year
	o give rise to situations arant. sentation required, with travel/acc	o give rise to situations of conflict of integrant.	give rise to situations of conflict of interest arant. Sentation required, with travel/accommodation fees covered or inder Comments Start (day (op	give rise to situations of conflict of interest arant. sentation required, with travel/accommodation fees covered or indemnity paid

Elected positions and mandates currently held

6.